Cardiovascular effects of chronic treatment with a beta2-adrenoceptor agonist relieving neuropathic pain in mice

Citer cette référence
CHOUCAIR-JAAFAR, Nadia, BEETZ, N., GILSBACH, R., YALCIN-CHRISTMANN, Ipek, WALTISPERGER, Elisabeth, FREUND, Marie-Jose J., MONASSIER, Laurent, HEIN, L. et BARROT, Michel, 2011. Cardiovascular effects of chronic treatment with a beta2-adrenoceptor agonist relieving neuropathic pain in mice. Neuropharmacology [en ligne]. 23 février 2011. Vol. 61, n° 1pp. 51-60. [Consultésans date]. DOI 10.1016/j.neuropharm.2011.02.015. Consulté de : http://www.sciencedirect.com/science/article/pii/S0028390811000852?via%3Dihub1. .
Pas de texte intégral
Auteurs Nadia Choucair-Jaafar
N Beetz
R Gilsbach
Ipek Yalcin-Christmann
Elisabeth Waltisperger
Marie-Jose Freund
Laurent Monassier
L Hein
Michel Barrot
Unité de recherche du site Institut des Neurosciences Cellulaires et Intégratives - INCI - UPR3212
Laboratoire de neurobiologie et pharmacologie cardiovasculaire - LNPCV – EA7296
Langue

en
Volume

61
Numéro

1-2
Page de début

51
Page de fin

60
Date de première publication

2011-02-23
Date de parution

2011-07
ISSN

1873-7064
Titre de la source (revue, livre…)

Neuropharmacology
Résumé

Neuropathic pain is often a chronic condition, disabling and difficult to treat. Using a murine model of neuropathic pain induced by placing a polyethylene cuff around the main branch of the sciatic nerve, we have shown that chronic treatment with Show moreNeuropathic pain is often a chronic condition, disabling and difficult to treat. Using a murine model of neuropathic pain induced by placing a polyethylene cuff around the main branch of the sciatic nerve, we have shown that chronic treatment with beta-AR agonists is effective against neuropathic allodynia. beta-mimetics are widely used against asthma and chronic obstructive pulmonary disease and may offer an interesting option for neuropathic pain management. The most prominent adverse effects of chronic treatment with beta-mimetics are cardiovascular. In this study, we compared the action of low doses of the selective beta(2)-AR agonist terbutaline and of a high dose of the mixed beta(1)/beta(2)-AR agonist isoproterenol on cardiovascular parameters in a neuropathic pain context. Isoproterenol was used as a positive control for some heart-related changes. Cardiac functions were studied by echocardiography, hemodynamic measurements, histological analysis of fibrosis and cardiac hypertrophy, and by quantitative real time PCR analysis of atrial natriuretic peptide (Nppa), periostin (Postn), connective tissue growth factor (Ctgf) and beta-myosin heavy chain (Myh7). Our data show that a chronic treatment with the beta(2)-AR agonist terbutaline at low antiallodynic dose does not affect cardiovascular parameters, whereas the mixed beta(1)/beta(2)-AR agonist isoproterenol induces cardiac hypertrophy. These data suggest that low doses of beta(2)-AR agonists may provide a suitable treatment with rare side effects in neuropathic pain management. This study conducted in an animal model requires clinical confirmation in humans. Show less
DOI 10.1016/j.neuropharm.2011.02.015
Éditeur

Elsevier
URL éditeur http://www.sciencedirect.com/science/article/pii/S0028390811000852?via%3Dihub
Type de publication

journal article
Type de publication

ACL
Domaine

Aucun
Équipes de recherche

E5 - Approche anatomo-fonctionnelle et traitement de la douleur chronique
Fonction

aut
Identifiant idREF 146443713
127246797
Audience

Non spécifiée
URL https://univoak.eu/islandora/object/islandora:57611